• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Aptar wins FDA clearance for ready-to-use seizure treatment device

December 9, 2019 By Danielle Kirsh

aptar-logoAptarGroup today said it won FDA approval for its Unidose Liquid System that treats acute repetitive seizures in people who have epilepsy.

The Unidose Liquid System is a device that delivers a nasal rescue treatment that is ready-to-use when and where a seizure cluster occurs.

“This approval and successful market launch further demonstrate the broad potential for Aptar’s patient-friendly drug delivery solutions and services offerings which help our pharmaceutical customers address unmet healthcare needs,” president and CEO of Aptar Stephan Tanda said in a news release. “We are pleased to offer a broad portfolio of innovative technologies and wide array of services to meet the highest quality standards of the pharmaceutical industry.”

Aptar’s Unidose Liquid System is a single-use, one-step nasal delivery device that is designed to be administered by a non-healthcare professional to someone during or after a seizure. The patient or caregiver presses a small plunger on the bottom of the device that releases the drug in a single spray into the nostril where the nasal mucosa quickly absorbs the drug.

“The launch of our Unidose System on the first and only U.S. FDA approved nasal rescue treatment for seizure activity once again demonstrates Aptar Pharma’s ability to help out customers develop and launch complex treatments,” president of Aptar Pharma Gael Touya said. “When we combine our nasal systems’s capabilities with Noble’s training devices for on boarding, we bring added value to our customers and further convenience for patients and consumers worldwide.”

Filed Under: Drug-Device Combinations, Pharmaceuticals Tagged With: aptarpharma, epilepsy

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

About Danielle Kirsh

Danielle Kirsh is an award-winning journalist and senior editor for Medical Design & Outsourcing, MassDevice, and Medical Tubing + Extrusion, and the founder of Women in Medtech and lead editor for Big 100. She received her bachelor's degree in broadcast journalism and mass communication from Norfolk State University and is pursuing her master's in global strategic communications at the University of Florida. You can connect with her on Twitter and LinkedIn, or email her at dkirsh@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS